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Abstract
Objectives
Since lipid compounds are known to modulate the function of CD4+ T-cells and macro-
phages, we hypothesize that altered levels of serum non-esterified fatty acids (NEFA) may
underlie rheumatoid arthritis (RA) pathogenesis.
Methods
Serum levels of NEFA (palmitic, stearic, palmitoleic, oleic, linoleic, γ-linoleic, arachidonic –
AA–, linolenic, eicosapentaenoic –EPA– and docosahexaenoic –DHA–) were quantified by
LC-MS/MS after methyl-tert-butylether (MTBE)-extraction in 124 RA patients and 56
healthy controls (HC). CD4+ phenotype was studied by flow cytometry. TNFα, IL-8, VEGF,
GM-CSF, IFNγ, IL-17, CCL2, CXCL10, leptin and resistin serum levels were quantified by
immunoassays. The effect of FA on IFNγ production by PBMC was evaluated in vitro.
Results
Lower levels of palmitic (p<0.0001), palmitoleic (p = 0.002), oleic (p = 0.010), arachidonic
(p = 0.027), EPA (p<0.0001) and DHA (p<0.0001) were found in RA patients, some NEFA
being altered at onset. Cluster analysis identified a NEFA profile (hallmarked by increased
stearic and decreased EPA and DHA) overrepresented in RA patients compared to HC (p =
0.002), being associated with clinical features (RF, shared epitope and erosions), increased
IFNγ expression in CD4+ T-cells (p = 0.002) and a Th1-enriched serum milieu (IFNγ, CCL2
and CXCL10, all p<0.005). In vitro assays demonstrated that imbalanced FA could underlie
IFNγ production by CD4+ T-cells. Finally, changes on NEFA levels were associated with
clinical response upon TNFα-blockade.
Conclusion
An altered NEFA profile can be found in RA patients associated with clinical characteristics
of aggressive disease and enhanced Th1 response. These results support the relevance of
lipidomic studies in RA and provide a rationale for new therapeutic targets.
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Introduction
Rheumatoid Arthritis (RA) is a rheumatic condition associated with joint erosion and destruc-
tion caused by an immune response against self-antigens. Autoimmune mechanisms orches-
trating its pathogenesis have been conventionally considered to be regulated by genes and
proteins. However, in the era of the “omics” sciences, metabolomics -and especially lipidomics-
are changing this dogma by the identification of novel players [1,2]. Among them, lipids are
emerging as potential pivotal candidates.
Largely considered as simple energy stores and structural components, lipid compounds are
currently known to actively control a number of biological processes. The notion that lipid spe-
cies can shape the immune response is currently becoming accepted [3–5], although the exact
players of this crosstalk remain largely unclear. Interestingly, changes in lipid depots are related
to changes in gene expression and function in monocytes and CD4+ T-cells through secreted
compounds [6–8], the non-esterified fatty acids (NEFA) being the main responsible of these
effects. Accordingly, NEFA are known to be involved in a number of relevant processes for the
immune system, such as modulation of the production of cytokines and chemokines [9–11],
expression of adhesion molecules [12,13] as well as the release of proinflammatory and anti-
inflammatory lipid-derived compounds [14,15]. Therefore, it is tempting to speculate that
altered levels of NEFA would underlie a disturbed, poorly controlled, immune response. How-
ever, to what extent these mechanisms are relevant for human immune-mediated diseases is
unknown.
Although some metabolomic studies have been performed in RA [16–18], little evidence on
NEFA has been reported. Additionally, no standardized protocols are available for NEFA anal-
ysis, and lipid analyses have been accompanied by technical issues only partly overcome recent
years [19]. Actually, results on NEFA until date show a considerable variation even within
healthy (control) populations. Recently, some authors have revealed the presence of different
NEFA on synovial fluid (SF) in RA patients, but the clinical relevance of these findings was not
studied [20]. Consequently, which the serum NEFA profile in RA patients is and whether it
could be associated with clinical features remain unknown. Elucidation of serum NEFA profile
in RA would provide new insight into the pathological mechanisms underlying this condition
and it would also lead to the identification of novel biomarkers for clinical management. There-
fore, the main aims of the present study were (i) to analyze the levels of serum NEFA in RA
patients, (ii) to investigate their association with clinical features and (iii) to elucidate whether
NEFA profiles may be linked to the impaired CD4+ T-cell response in RA.
Methods
Ethics approval
Approval for the study was obtained from the Institutional Review Board (Comité Regional de
Investigación Clínica del Principado de Asturias), in compliance with the Declaration of Hel-
sinki. All the participants gave written informed consent prior to their inclusion in the study.
All methods were carried out in accordance with the approved guidelines.
Patients and controls
Our study involved 124 RA patients recruited from the Department of Rheumatology at Hospi-
tal Universitario Central de Asturias. All of them fulfilled the 2010 American College of Rheu-
matology classification criteria for RA. Some RA patients were recruited when the clinical
diagnosis of RA was established, thereby exhibiting no previous exposure to any treatment (RA
onset, n = 18). A complete clinical examination, including Disease Activity Score 28-joints
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(DAS28) calculation, was performed on each patient during their clinic appointment and an
overnight fasting blood sample was drawn by venipuncture. Additionally, 13 biologic-naïve RA
patients (12 women, median age 43 (range: 30–65), DAS28 5.08(1.93), 38.5% RF+, 46.1%
ACPA+), candidates for anti-TNFα therapy, were prospectively followed for three months.
Blood samples were collected immediately before and 3 months after TNFα-blocking therapy.
Clinical response was evaluated by EULAR criteria.
Simultaneously, 56 age- and gender- and BMI-matched healthy individuals (HC) were
recruited from the general population (42 female, age (mean±SD): 48.98±7.75 years, BMI: 25.8
(4.58)). Automated serum lipids analysis was carried out on all the participants from fasting
fresh blood samples. Serum samples were stored at -80°C until analyses.
NEFA extraction
A new methyl-tert-butylether (MTBE)-based extraction protocol was developed following
Pizarro et al. [19,21]. Briefly, to 50 μl serum 5 μl of internal standard (300 ppm heptadecanoic
acid) and 150 μl methanol chromasolv grade (Sigma) were added and tubes were vortexed for
30 s. Then, 750 μl MTBE chromasolv grade (Sigma) were added, vortexed and an incubation
for 30 minutes in a ultrasound (US)-assisted water bath at 15°C was performed. For phase sep-
aration, 125 μl milliQ water were added, vortexed and centrifuged for 7 minutes at 5000 rpm
(15°C). Organic phase was collected and the extraction steps were repeated once with 100 μl
MetOH, 300 μl MTBE and 100 μl milliQ H2O.
Lipid extracts were dried in a miVac centrifugal evaporator (Genevac Ltd), and redissolved
in 500 μl of water:acetonitrile 38:62.
LC-MS/MS analysis
For the determination of the fatty acids, an Agilent 1290 Infinity HPLC system (Santa Clara),
consisting of a high pressure binary pump, an autosampler and a column oven, was used. The
column was a Zorbax Eclipse Plus (Agilent) C18, 50x2.1 mm, 1.8 μm. Mobile phases A and B
were water and acetonitrile respectively, both containing formic acid 0.1%. Fatty acids separa-
tion was carried out by the following gradient program: 62% B (held for 4.5 min) followed by a
linear increase up to 100% B in 10 min (held for 1 min). The column temperature was set at
45°C and the injection volume was 2 μl.
Mass detection was performed using an Agilent 6460 triple quadrupole mass spectrometer
with electrospray ionization, operated in the negative SIM mode (S1 Fig). The settings of the
mass spectrometer were as follows: spray voltage 3.5 kV; gas flow 9 l/min; gas temperature 300°
C; nebulizer pressure 50 psi; sheath gas flow 11 l/min at 350° C.
For quantitation, calibration curves for each compound were prepared by proper dissolu-
tion of the pure (>99%) standards (all from Sigma) in methanol to encompass the expected con-
centration of the analytes in the sample. The calibration ranges were 0.4–12.5 μg/ml for EPA and
γ-linolenic; 1.2–37.5 μg/ml for DHA and linolenic; 2.3–75 μg/ml for AA and palmitoleic; 7.8–
250 μg/ml for oleic and linoleic and 15.6–500 μg/ml for palmitic and stearic. Detection limits
were as follows: 0.10 μg/ml EPA, 0.46 μg/ml DHA, 0.01 μg/ml AA, 0.01 μg/ml γ-linolenic,
0.42 μg/ml linolenic, 0.04 μg/ml palmitoleic, 0.45 μg/ml linoleic, 0.34 μg/ml palmitic, 1.01 μg/ml
oleic and 1.91 μg/ml stearic. A good linearity was observed in all cases (r2>0.994). Internal stan-
dard was used to correct for potential variations during the sample preparation step.
Total NEFA measurement
Total serum NEFA level was measured using an enzymatic colorimetric assay (NEFA kit,
Roche). Maxisorp Nunc plates were used and absorbance was recorded at 546 nm, following
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manufacturer instructions. Standard curves between 1.50 and 0.02 mM were included and
intra- and inter-assay coefficients of variation were 9.42 and 10.0%, respectively.
Flow cytometry analysis
CD4+ phenotype was analyzed by flow cytometry as previously described [22]. Briefly, 300 μl
peripheral blood were stained with anti-CD4 APC-Cy7 (Immunostep) and anti-CD25 FITC
for 30 minutes at 4°C. Then, erythrocytes were lysed and cells were fixed and permeabilized
(FOXP3 transcription factor staining kit, eBioscience) and intracellularly stained with anti-
FOXP3 PE, anti-IFNγ PerCP-Cy 5.5 and anti-IL17 APC (all eBiosciences) or isotype controls
(eBioscience). Samples were analyzed and 50,000 CD4+ lymphocytes were acquired in a FACS
Canto II (BD) cytometer. CD4+ cells were gated and their intensity of IFNγ and IL-17 intracel-
lular staining (measured as mean fluorescence intensity, MFI) was analyzed with FACS Diva v.
2.6 (BD) by subtracting the MFI in the isotype control tube to that of the specific antibody-
stained one. Regulatory T cells (Treg) were identified as CD4+CD25highFOXP3+.
Culture assays
Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation on Ficoll (Lym-
phoprep, PAA) gradients from buffy coat preparations obtained from healthy donors and
washed twice with sterile PBS. Then, cells were cultured for 48 h in 48-well plates at 2106 cells/
ml in RPMI 1640 (Bio Witthaker) with 10% heat-inactivated FCS (PAA) and 100 μg/ml strep-
tomycin and ampicillin (Sigma) in the presence of different concentrations of stearic, DHA
and EPA fatty acids dissolved in DMSO (Sigma) under resting conditions or with 2.5 μg/ml
phytohaemagglutinin A (PHA) (Sigma). Negative controls were treated with the same amount
of DMSO. FA concentrations (stearic and DHA: 25, 50 and 100 μM; EPA: 25 and 50 μM) were
determined by previous experiments among those not exhibiting cytotoxic effects. Parallel cul-
tures were performed either to analyze culture supernatants or intracellular production of cyto-
kines. To assess the production of cytokines, cells were treated with 20 ng/ml phorbol-
12-myristate-13-acetate (PMA), 500 ng/ml ionomycin and 2 μMmonensin (all from Sigma)
for 5 hours. Then, cells were processed as previously described for flow cytometry analysis of
intracellular IFNγ accumulation. Propidium iodide was used to exclude non-viable cells.
Quantification of cytokines
IFNγ levels were analyzed in serum samples and culture supernatants with an OptEIA kit (BD)
following manufacturer’s instructions. Detection limit was 0.58 pg/ml. Serum levels of IL-8,
VEGF, IL-17 and GM-CSF were measured with a CBA kit (BD) according to developer’s rec-
ommendations. Detection limits were 1.2 pg/ml, 4.5 pg/ml, 0.3pg/ml and 0.2 pg/ml, respec-
tively. TNFα, CCL2 (MCP-1), CXCL10 (IP-10), Resistin and Leptin were assessed with Mini-
EDK ELISA kits (Peprotech). Detection limits were 3.9 pg/ml, 8 pg/ml, 3.9 pg/ml, 63 pg/ml
and 24 pg/ml, respectively.
Statistical analysis
Continuous variables are summarized as median (interquartile range) or mean ± standard
deviation whereas n(%) was used for categorical ones. Differences between two groups were
evaluated by MannWithney U tests, whereas Kruskal-Wallis or one-way ANOVA were chosen
when more than two groups were included. Dunn-Bonferroni or Bonferroni corrections for
multiple comparisons were carried out when Kruskal-Wallis tests exhibited significant differ-
ences, and p-values for each comparison are shown. Categorical variables were analyzed by χ2
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square or Fisher exact tests. Paired t tests were performed on prospective samples. Correlations
were analyzed by Spearman’s rank test. Principal Component Analysis (PCA) with Varimax
rotation was performed. The number of components retained was based on eightenvalues (>1)
and loadings greater than 0.5 were used to identify the variables comprising a single compo-
nent. For cluster analysis, squared euclidean distances were computed from PCA scores in
order to avoid biases due to redundant information and differences in ranges among variables,
and Ward’s Minimum Variance Method was used to identify clusters minimizing the loss of
information. Heatmap were built with R package heatmap.2 for visualization purposes. Find-
ings from correlation analyses and size effect (Hedges’s statistic) were considered to choose
candidate individual FA for in vitro assays. SPSS 19.0, R 3.0.3 and GraphPad Prism 5.0 for
Windows were used.
Results
NEFA levels in HC and RA patients
Individual and total serum NEFA levels were measured in 124 RA patients (Table 1) and 56
healthy controls (HC) and the results are summarized in Table 2. Total NEFA levels were simi-
lar in patients and controls but palmitic, palmitoleic, oleic, AA, EPA and DHA were decreased
in RA patients. Differences were unrelated to age, gender or BMI. No effect of disease activity
on NEFA levels was detected in RA, but disease duration was positively correlated with stearic
levels (r = 0.364, p<0.001) and negatively with palmitic (r = -0.252, p = 0.007), palmitoleic
(r = -0.236, p = 0.012), AA (r = -0.389, p<0.001), EPA (r = -0.243, p = 0.009) and DHA (r =
-0.260, p = 0.006) (S2 Fig). However, linoleic and DHA were impaired in patients without pre-
vious exposure to treatments (RA onset) (S1 Fig), thereby supporting that other factors than
disease duration are responsible for the NEFA disturbances in RA. Interestingly, higher levels
of stearic were found in patients with established disease compared to their early counterparts
(p = 0.016).
Differences in the individual NEFA remained after correction by the total NEFA level, thus
pointing to an altered NEFA profile in RA patients. Of note, altered FA exhibited diverse chain
length and double bound location, so impairment of NEFA levels cannot be solely attributed to
their chemical properties.
Since a number of correlations between individual NEFA levels were found, we conducted a
PCA on the NEFA in order to exclude potential collinearity biases and avoid loss of informa-
tion. All NEFA showed communalities higher than 0.5, and both the Kaiser-Meyer-Olkin test
(0.716) and the Bartlett test of sphericity (p = 10−123) provided a good adequacy of the data and
explained 77.58% of the total variation. PCA resulted in 4 components: C1 (including AA, EPA
and DHA), C2 (including palmitic, oleic, linoleic and γ-linolenic), C3 (including palmitoleic
and linolenic) and C4 including (stearic). Therefore, PCA analysis revealed that individual
NEFA within a given class seem to follow distinct patterns and similar patterns were found
among different groups of NEFA.
NEFA profile in RA patients and its associations with clinical features
Since our results pointed to an altered NEFA profile in RA, we wondered whether it could be
found in the whole RA population or if, on the contrary, NEFA profiles may be associated with
specific clinical characteristics. To this aim, a cluster analysis was performed from PCA scores.
Results from the cluster analyses revealed the existence of two groups with different pattern
and levels of individual NEFA, so we referred to them as NEFAhigh and NEFAlow profiles.
Interestingly, the distribution of NEFA profiles was different between patients and HC, the
NEFAlow profile being almost absent in HC (3/56) compared to the RA group (30/124,
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p = 0.002). When NEFA levels were plotted in a heatmap (Fig 1), HC and NEFAhigh RA
patients clustered together, whereas NEFAlow RA patients formed a separate group. NEFAlow
profile was hallmarked by increased stearic levels in combination with decreased palmitic, EPA
and DHA (S2 Table) (Fig 1). No differences in total NEFA levels were found among profiles in
RA.
Next, we analyzed whether the NEFA profiles were associated with clinical features in RA
patients. Whereas no differences in age, gender, traditional CV risk factors or treatments were
observed, the NEFAlow profile was associated with higher disease duration, RF positivity and
Table 1. Demographic and clinical parameters of RA patients.
RA patients(n = 124)
Gender (female:male) 99:25
Age at sampling, years (mean±SD) 52.47 ± 12.76
Disease features
Disease duration, years, median (range) 4.91 (0.00–30.00)
Age at diagnosis, years (mean±SD) 46.39 ± 12.70
Recruited at onset, n(%) 18 (14.5)
BMI 26.43 (6.38)
Disease activity (DAS28) 3.70 (2.08)
Tender Joint Count 2.00 (7.50)
Swollen Joint Count 1.50 (5.00)
Patient Global Assessment (0–100) 42.00 (40.00)
ESR, mm/h 16.00 (22.75)
CRP, mg/l 2.00 (4.00)
HAQ (0–3) 0.93 (1.22)
RF (+), n(%) 76 (61.2)
ACPA (+), n(%) 74 (59.6)
ANA (+), n(%) 68 (54.8)
Shared epitope, n(%) [n = 91] 54 (59.3)
Shared epitope (2 copies), n(%) [n = 91] 13 (14.2)
Erosive disease, n(%) 48 (38.7)
Traditional CV risk factors, n(%)
Dyslipidemia 43 (34.6)
Hypertension 40 (32.2)
Diabetes 11 (8.8)
Obesity (BMI>30) 26 (20.9)
Smoking habit 43 (34.6)
Previous CV events 18 (14.5)
Treatments, n(%)‡
Glucocorticoids 56 (52.8)
Methotrexate 87 (82.0)
TNFα blockers 44 (41.5)
Tocilizumab 12 (11.3)
Statins 23 (21.6)
Continuous variables are summarized as median (interquartile range) and n(%) was used for categorical
ones, unless otherwise was stated.
‡ Frequency of treatments are calculated excluding patients recruited at diagnosis (untreated, n = 18)
(n = 106)
doi:10.1371/journal.pone.0159573.t001
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erosive disease (Table 3). Moreover, patients carrying two copies of the shared epitope were
more likely to exhibit a NEFAlow profile. Since these associations may be attributed to the lon-
ger disease duration, patients at onset (n = 18) were excluded from the analysis, but the associa-
tions remain significant. Overall, these results suggest that a specific NEFA profile is found in
RA linked to markers of aggressive disease.
NEFA profile in RA patients and immune parameters
Given the proposed role of certain FA as mediators of inflammatory responses, we explored
whether increased Th1 or Th17 responses, usually found in RA patients, may be associated
with NEFA profiles. Therefore, both effector (IFNγ+ or IL-17+) and regulatory (Foxp3+) CD4+
T-cells as well as cytokine serum levels were analyzed in patients and controls (Table 4).
Concerning the CD4+ phenotype, flow cytometry analyses showed that NEFAlow profile was
related to increased IFNγ expression, but no associations were observed in the frequency of
total CD4+ T-cells, Treg or IL-17 expression levels.
Although RA patients exhibited raised levels of proinflammatory cytokines compared to
HC, some striking differences were noted between NEFA profiles. NEFAlow RA patients exhib-
ited increased IFNγ serum levels, thus highlighting a link between NEFA profile and increased
IFNγ production both at cellular and systemic level. NEFAlow profile was also related to
increased CCL2 and CXCL10 (both Th1-related chemokines) as well as GM-CSF. Interestingly,
IFNγ concentration paralleled levels of stearic acid (r = 0.416, p<0.001) whereas a negative
association was found with EPA (r = -0.247, p = 0.009) and DHA (r = -0.263, p = 0.006) (S2
Fig). Therefore, all these results support an association between an increased Th1-related cyto-
kines response in RA patients and their NEFA profile, stearic, DHA and EPA having a poten-
tial role.
NEFA can modulate IFNγ production by CD4+ T-cells
To elucidate whether individual NEFA or an altered NEFA profile could promote an excessive
IFNγ response, in vitro studies were conducted to evaluate the effect of individual NEFA which
hallmarked the NEFAlow profile on the production of IFNγ by PBMC. Candidate NEFA were
chosen within those which were more differentially present between groups (based on p-values
Table 2. Individual and total NEFA serum levels in the study participants.
NEFA (μg/ml) HC(n = 56) RA patients(n = 124) p-value
Palmitic (16:0) 1624.48 (763.33) 1000.69 (714.19) < 0.0001
Stearic (18:0) 311.70 (118.84) 317.65 (79.47) 0.149
Palmitoleic (16:1w7) 14.67 (9.56) 10.09 (7.50) 0.002
Oleic (18:1w9) 297.79 (153.51) 209.21 (230.51) 0.010
Linoleic (18:2w6) 200.41 (143.00) 153.79 (156.60) 0.084
γ-linoleic (18:3w6) 1.44 (0.27) 1.42 (0.45) 0.920
AA (20:4w6) 11.16 (4.93) 9.27 (5.11) 0.027
Linolenic (18:3w3) 9.29 (3.74) 7.95 (5.05) 0.069
EPA (20:5w3) 2.62 (1.11) 1.90 (1.03) < 0.0001
DHA (22:6w3) 12.55 (11.69) 7.80 (6.26) < 0.0001
Total NEFA (mM) 0.41 (0.19) 0.47 (0.34) 0.157
Serum levels of individual NEFA (μg/ml, measured by LC-MS/MS) and total NEFA (mM, measured by an
enzymatic colorimetric assay) are summarized as median (interquartile range) and differences were
assessed by MannWithney U test.
doi:10.1371/journal.pone.0159573.t002
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and Hedges’g statistic as a measure of the size effect) and which were also associated with IFNγ
in univariate analysis. Therefore, the effect of stearic, DHA and EPA was evaluated by analyz-
ing IFNγ release and IFNγ-producing CD4+ T-cells in PBMC cultures.
Fig 1. NEFA levels in HC and RA patients.Heatmap of NEFA serum levels showing the different NEFA species
(columns). Each row corresponds with an individual. Colours in the vertical bar at the left of the heatmap identifies
healthy controls (yellow), NEFAhigh RA patients (brown) and NEFAlow RA patients (gray). Since NEFAlow profile was
very infrequent in HC, controls were not divided into NEFA profiles. Tiles are coloured based on serum NEFA
concentrations, red and blue indicating low or high levels, respectively.
doi:10.1371/journal.pone.0159573.g001
NEFA Profiles in Rheumatoid Arthritis
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After 48h of culture, stearic acid promoted an increase in IFNγ secretion in both resting and
PHA-stimulated cells (Fig 2A). No effect for EPA and DHA was seen under resting conditions,
although both NEFA inhibited PHA-stimulated IFNγ release. These findings were also noted
when IFNγ accumulation in CD4+ T-cells was evaluated after PMA and ionomycin treatment
of both resting and PHA-stimulated cells. No effect on CD4+ frequency or viability was
observed at the concentrations tested (resting: p = 0.392 and p = 0.334; PHA: p = 0.998 and
p = 0.292, respectively).
Therefore, stearic and EPA/DHA exhibited an opposite effect on IFNγ production that
seems to be mediated, at least in part, by CD4+ T-cells. In order to evaluate the combined effect
Table 3. NEFA profiles and clinical features.
NEFAhigh(n = 94) NEFAlow(n = 30) p-value
Gender (female:male) 75:19 24:6 0.980
Age at sampling, years (mean±SD) 52.29 ± 13.65 52.86 ± 11.34 0.949
Disease features
Disease duration, years, median (range) 3.83 (0.00–30.00) 7.04 (2.17–17.50) 0.002
Age at diagnosis, years (mean±SD) 46.92 ± 13.46 44.90 ± 10.32 0.325
Recruited at onset, n(%) 18 (19.1) 0 (0.0)
BMI 26.43 (6.83) 26.37 (6.57) 0.310
Disease activity (DAS28) 3.88 (2.40) 3.52 (1.36) 0.230
Tender Joint Count 3.00 (7.00) 1.50 (5.00) 0.064
Swollen Joint Count 2.00 (5.00) 0.00 (2.50) 0.059
Patient Global Assessment (0–100) 47.00 (45.00) 37.50 (38.50) 0.087
ESR, mm/h 18.00 (23.50) 12.00 (22.00) 0.600
CRP, mg/l 1.65 (4.00) 2.30 (4.28) 0.244
HAQ (0–3) 1.00 (1.16) 0.87 (1.15) 0.173
RF (+), n(%) 52 (55.3) 24 (80.0) 0.029
ACPA (+), n(%) 52 (55.3) 22 (73.3) 0.184
ANA (+), n(%) 48 (51.0) 20 (66.6) 0.202
Shared epitope, n(%) [n = 91] 43 (60.5) 11 (55.0) 0.655
Shared epitope (2 copies), n(%) [n = 91] 5 (7.0) 8 (40.0) <0.001
Erosive disease, n(%) 29 (30.8) 19 (63.3) 0.003
Traditional CV risk factors, n(%)
Dyslipidemia 30 (31.9) 13 (43.3) 0.286
Hypertension 31 (32.9) 9 (30.0) 0.735
Diabetes 8 (8.5) 3 (10.0) 0.816
Obesity (BMI>30) 23 (24.4) 3 (10.0) 0.069
Smoking habit 29 (30.8) 14 (46.6) 0.122
Previous CV events 13 (13.8) 5 (16.6) 0.701
Treatments, n(%)‡
Glucocorticoids 48 (63.1) 20 (66.6) 0.494
Methotrexate 63 (82.8) 24 (80.0) 0.521
TNFα blockers 28 (36.8) 16 (53.3) 0.163
Tocilizumab 7 (9.2) 5 (16.6) 0.297
Statins 16 (21.0) 7 (23.3) 0.634
Continuous variables are summarized as median (interquartile range) and n(%) was used for categorical ones, unless otherwise was stated. Differences
were analyzed by MannWithney U, χ2 square or Fisher exact tests, as appropriate.
‡ Frequency of treatments are calculated excluding patients recruited at diagnosis (untreated, n = 18) (NEFAhigh: n = 76, NEFAlow: n = 30)
doi:10.1371/journal.pone.0159573.t003
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of these NEFA, PBMC were cultured in the presence of stearic acid (50 μM) alone or in combi-
nation with increasing amounts of both DHA and EPA (25 or 50 μM each). Our results clearly
demonstrate that DHA and EPA were able to counteract the stearic-mediated IFNγ production
in both resting and PHA-stimulated PBMC (Fig 2B). Again, this effect was observed at CD4+
T-cells level. Hence, our results support that the balance among stearic, DHA and EPA could
influence the IFNγ-CD4+ response.
NEFA profile upon therapeutic TNFα-blockade in RA patients
Finally, the changes on NEFA serum levels upon TNFα-blockade and its association with clini-
cal outcome were evaluated. To this end, NEFA serum levels were analyzed in a subgroup of
biological-naïve RA patients (n = 13) before and 3 months after TNFα-blockade initiation.
Anti-TNFα treatment was associated with decreasing EPA, DHA and AA levels in the
whole group (S3 Table). However, when patients were stratified by EULAR clinical response,
these NEFA declined in non-responders (NR, n = 8) but not in patients with a good clinical
response (R, n = 5). On the contrary, stearic levels showed a decrease in patients who exhibited
a good response but not in their NR-counterparts patients (S4 Table). Importantly, no differ-
ences in total NEFA levels were found.
Finally, although no effect of TNFα-blockade was observed on IFNγ serum levels (whole group:
p = 0.152, NR: p = 0.401, R: p = 0.138), decreasing IFNγ expression on CD4+ T-cells was found in
responders (91.00(33.00) vs 32.00(51.50), p = 0.043), but not in non-responders (p = 0.889). Inter-
estingly, no differences in the total CD4+ frequency (43.14(13.84) vs 44.70(14.63)%, p = 0.074) or
Treg subsets (0.94(0.60) vs 1.19(0.55)%, p = 0.170) were noted upon treatment.
These results suggest than decreasing EPA, DHA and AA levels are associated with poor
response to TNFα inhibitors, whereas decreasing stearic levels did with a good response.
Therefore, changes within NEFA serum pool may be connected with clinical outcome and
IFNγ-CD4+ immune response in RA patients upon TNFα-blockade.
Table 4. NEFA profiles and immune features.
HC(n = 56) NEFAhigh(n = 94) NEFAlow(n = 30) p-value(NEFA low vs high)
CD4+ phenotype
CD4+ T cells (%) 43.20 (14.76) 40.86 (17.86) 38.83 (12.54)
MFI IFNγ (CD4+) 33.50 (31.00) 40.50 (33.00) 57.00 (19.00)*** 0.002
MFI IL17 (CD4+) 44.85 (36.00) 45.00 (48.00) 54.00 (44.00)
CD4+CD25highFOXP3+ Treg cells (%) 0.74 (0.47) 1.03 (0.65) 1.05 (0.71)
Serum cytokines
TNFα, pg/ml 93.94 (181.89) 240.21 (264.24)*** 331.36 (346.39)*** 0.946
IL-8, pg/ml 14.84 (14.83) 43.13 (16.46)*** 43.48 (22.90)*** 0.931
IL-17, pg/ml 1.07 (6.95) 1.14 (21.85) 2.25 (80.34)
VEGF, pg/ml 103.89 (51.33) 113.34 (49.83) 118.08 (38.10)
GM-CSF, pg/ml 21.33 (1.40) 26.24 (7.15)*** 31.63 (15.56)*** < 0.001
IFNγ, pg/ml 3.29 (5.47) 3.66 (4.09) 5.90 (7.90)*** < 0.001
CCL2, pg/ml 244.50 (293.16) 252.97 (265.02) 931.49 (1089.94)*** < 0.0001
CXCL10, pg/ml 54.45 (41.40) 73.89 (104.80)* 147.75 (156.63)*** 0.006
Leptin, ng/ml 7.57 (8.33) 12.35 (14.41)** 10.17 (10.22)* 0.371
Resistin, pg/ml 6.78 (3.38) 9.74 (5.03)*** 9.83 (6.30)* 0.804
Variables are summarized as median (interquartile range) and differences were analyzed by Kruskal-Wallis (K-W) test with Dunn-Bonferroni correction for
multiple comparisons tests. When Kruskal-Wallis test revealed differences among groups, p-values of post hoc tests between NEFAlow and NEFAhigh
proﬁles were indicated in the right column, whereas differences between each NEFA proﬁle and HC are indicated as *p<0.050, **p<0.010, ***p<0.001.
doi:10.1371/journal.pone.0159573.t004
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Discussion
Several studies have recently focused on lipidomic approaches in a number on human diseases.
Here we report the first results on NEFA quantification in RA and their associations with clini-
cal features. Although other authors have previously performed a lipid profiling on SF from
RA patients [20], our results went further by assessing the differences compared to a control
population and their associations with clinical parameters, thus gaining insight on the clinical
Fig 2. Effect of FA added alone or in combination on IFNγ production in vitro. (A) Effect of the addition of individual FA to PBMC cultures. The effect
of individual FA (stearic, DHA and EPA) on IFNγ production by PBMCs under resting conditions or in the presence of PHA was evaluated in culture
supernatants by ELISA or by flow cytometry on CD4+ T cells (both n = 6) (B) Effect of FA added in combination to PBMC cultures. The effect of different
combinations of FA on IFNγ production was examined (n = 6). DHA and EPA were added at a final concentration of 25 or 50 μM each. Differences were
assessed by ANOVA with Bonferroni multiple’s comparisons test and differences observed within pairs of groups are indicated as *p<0.050, **p<0.010 and
***p<0.001. Representative dot plots of flow cytometry quantification of IFNγ intracellular accumulation on gated CD4+ cells are shown. C: FA-untreated
cells used as controls for each experiment (resting cells or PHA-stimulated cells).
doi:10.1371/journal.pone.0159573.g002
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relevance of lipidomic profiling. Similarly, we focused on serum samples, which are easier to
obtain and are more interesting to biomarker discovery than SF. Moreover, since systemic
autoimmunity precede the synovial destruction [23], serum profiling exhibit additional advan-
tages to unravel disease mechanisms. Finally, we have adapted an innovative method for NEFA
extraction and analysis by LC-MS/MS from serum samples, with important advantages on effi-
ciency, reproducibility, reliability and minimizing time-consuming steps [21]. Additionally, we
have included an additional step to correct for total NEFA levels in serum by an independent
technique, thus excluding the possibility that our results are based on differences in the total
NEFA pool among individuals.
An important conclusion from our findings is the lack of a general pattern in NEFA
impairment in RA, not being specific NEFA classes globally altered, but individual NEFA
seemed to follow different patterns. The idea of different figures among same-class lipids was
highlighted by other authors studying healthy adults [24], and put into question therapies
based on lipid classes instead of individual lipid compounds.
The most outstanding result of our work is the identification of a NEFA profile associated
with features of aggressive disease and increased Th1-related cytokines in RA patients. Simi-
larly, altered expression of genes involved in FA metabolism has been reported in RA [25], as
well as in individuals with pre-clinical RA [26]. Moreover, decreased ω3-FA content in erythro-
cytes was reported in HLA-DR4+ individuals with high risk of developing RA [27]. Accord-
ingly, our results revealed altered NEFA levels, mainly EPA and DHA, in patients recruited an
onset (medications-free) and also in association with SE, therefore suggesting that NEFA
impairment could be an early event in RA, and not just a consequence of the disease course
itself or the exposure to different treatments, thereby supporting the role of NEFA species in
RA pathogenesis. Importantly, no effect of treatments was observed in the cross-sectional anal-
ysis. Although an association with glucocorticoid usage may have been expected, low doses of
corticoids prescribed to RA patients may explain our findings.
Interestingly, the altered NEFA profile was linked to clinical characteristics but not to tradi-
tional CV risk factors, thereby excluding an effect of important metabolic alterations (such as
diabetes or dyslipidemia) on the NEFA profiles found in RA. Then, particular alterations,
rather than a global impairment on FA metabolism, may cause these profiles.
The NEFAlow profile seem to underlie changes in immune parameters, since increased IFNγ
serum levels and IFNγ expression on CD4+ T-cells were found in NEFAlow patients. The fact
that CCL2 and CXCL10 were also increased lead us to think that altered NEFA could underlie
an excessive Th1 response. Although it is known that adipose tissue-infiltrating leukocytes
exhibit a Th1 phenotype [28,29], and that adipocytes can modulate CD4+ T-cell function by
secreted lipids in vitro [6], the clinical relevance of these findings is unknown. Our results are
the first evidence that this effect can be elicited by specific NEFA in the systemic compartment
in patients. However, the actual mechanisms by which NEFA drive these changes in CD4+ T-
cells are not totally understood. Based on the current literature, it is tempting to speculate that
peroxisome proliferator-activated receptors (PPAR) have a pivotal role. PPAR can bind poly-
unsaturated FA and eicosanoids [30,31], and their activation lead to the inhibition of several
inflammatory genes, including NFκB pathway [32–34]. Actually, PPAR-deficient mice exhibit
an uncontrolled response to inflammatory stimuli [30]. Thus, decreased FA-mediated PPAR
activation may account for the increased inflammatory response seen in NEFAlow. Interest-
ingly, IFNγ can be negatively regulated by PPAR [35] and NFκB [36] pathways. Conversely, in
spite of the role of the Th17 responses in RA, no associations were detected with the NEFA
profiles, either at the serum or the CD4+ T-cell level. Furthermore, whether the IFNγ produc-
tion could be underlie by a Th1 skewed response or it is solely attributed to a Th1 upregulation,
remains to be elucidated since the Th2 subset was not analyzed in the present study.
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Therefore, lower EPA and DHA at RA onset, or even at preclinical stages, could be unable
to counteract Th1 responses, especially in patients with particular clinical or genetic character-
istics, leading to an exacerbated inflammation. Moreover, changes in NEFA along the disease
course would additionally promote the Th1 shift, thus closing a pathogenic vicious circle. In
this scenario, our results point to DHA, EPA and stearic, a Th1-promoter NEFA associated
with disease duration, as relevant mediators of this phenomenon, as they hallmarked the
NEFAlow profile. In fact, the in vitro assays strongly support this idea. Hence, our findings shed
some light on the involvement of NEFA as pivotal players for immune dysregulation on the
basis of the Th1 response in RA. Therefore, strategies to counteract this NEFA imbalance
would be advisable.
Other interesting findings of our study are the changes on NEFA levels upon TNFα-block-
ade. Our results identify that a balance between stearic and both EPA and DHA is related to a
good clinical response in patients undergoing TNFα-blockade. Overall, our findings suggest
that effective TNFα neutralization may counteract the disease duration-dependent NEFA
impairment in RA. Moreover, changes in NEFA in good responders paralleled those of IFNγ.
Therefore, our results suggest that a poor clinical outcome is related to a NEFA profile similar
to NEFAlow. Then, tailored FA supplementation to counteract decreasing NEFA over time
could be advisable in these patients to increase the chance of achieving a good clinical response
upon biological treatment, as recently suggested for triple-DMARD therapy [37]. Although
largely explored, studies on FA supplementation in RA provided controversy results [38–40].
Overall, ω3-supplementation resulted in lower number of tender joints and pain scores [41],
but no effect on disease activity or immunological parameters was reported. Thus, these effects
can be attributed to an analgesic effect of ω3-derived products, whereas no effect on disease
progression, the actual clinical goal, is achieved. Some studies revealed a lower NSAIDs con-
sumption in the supplementation arm [39], thus supporting this idea. The results herein pre-
sented are particularly relevant for this issue. Since different NEFA profiles were observed, it is
conceivable that differences in supplementation requirements exist in RA, thereby stressing the
need for (i) an accurate stratification of patients according to their NEFA levels and (ii) a
detailed design of FA formulas for supplementation. Actually, when similar supplementation
interventions were performed, the effect was different among different conditions [42], thereby
supporting the relevance of tailored strategies. In RA patients, stratification could be guided by
clinical features as surrogate markers of NEFA impairment. Additionally, some concerns arise
on the design of FA supplements, since not only dosages but also ratios among FA are crucial,
following our results. Also, special attention needs to be paid when clinical trials are designed,
since some included oleic acid as control, although it was found to be decreased in some dis-
eases [43], including RA [38], where some beneficial effect was observed. Finally, chemical
structure of FA for supplementation can have an impact on their clinical effects [44].
Our results suggest that EPA/DHA dose-dependently abrogate IFNγ release in resting and
activated cells, thus supporting their use in supplementation schemes. There is limited evidence
of the effect of FA supplementation on IFNγ in humans [45]. However, different FA dietary
composition was found to modulate Th1-mediated bacterial clearance in mice [46]. Finally,
ω3-supplementation would have a beneficial effect on cardiovascular (CV) outcomes [47], the
most important comorbidity in RA. The link between NEFAlow profile and CCL2 may support
this notion.
In conclusion, we report for the first time an altered serum NEFA profile in RA, which is
associated with disease severity and enhanced Th1 CD4+ response. Equivalent results were
obtained when patients undergoing TNFα-blockade were followed, impaired NEFA levels
being related to a poor clinical outcome. Similarly, although some other NEFA may have an
effect on cytokine production, we decided to primarily focus on stearic, EPA and DHA. Apart
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from being an objective data-driven approach, it led to the identification of individual com-
pounds as responsible for the observed phenomena, with striking clues to unravel the disease
mechanisms as well as to identify potential therapeutic targets. Therefore, our results shed
some new light on the involvement of lipid species in RA pathogenesis and also provided a
rationale for FA supplementation, stratification and formula-design in RA. However, a role for
other NEFA or lipid species cannot be totally ruled out. Additional studies on lipid species on
RA immunopathology are warranted.
Supporting Information
S1 Fig. Chromatograms of serumMTBE-extracted fractions. Total Ion Current chromato-
grams (TIC) from a representative healthy control (black line) and a RA patient (red line) are
shown. Each peak represents a FA as follows: 1 (EPA), 2 (linolenic), 3 (γ-linolenic), 4 (palmito-
leic), 5 (DHA), 6 (AA), 7 (linoleic), 8 (palmitic), 9 (oleic), 10 (heptadecanoic) and 11 (stearic).
For peaks 1–4, a detailed Extracted Ion Chromatograms (EIC) corresponding to their specific
m/z values are provided (right).
(TIF)
S2 Fig. NEFA serum levels and disease duration. Analysis of the correlations between the dis-
ease duration and NEFA serum levels (stearic, palmitic, palmitoleic, AA, EPA and DHA) in
RA patients. Correlations were assessed by Spearman rank’s correlation tests, and coefficient
correlations and p-values are indicated for each analysis.
(TIF)
S3 Fig. NEFA and IFNγ serum levels. Analysis of the correlations between serum levels of
IFNγ and NEFA species (stearic, EPA and DHA) in RA patients. Correlations were assessed by
Spearman rank’s correlation tests, and coefficient correlations and p-values are indicated for
each analysis. IFNγ serum levels were log-transformed to facilitate visualization of these values.
(TIF)
S1 Table. Individual and total NEFA serum levels in RA patients stratified according to dis-
ease stages. Serum levels of individual NEFA (μg/ml, measured by LC-MS/MS) and total
NEFA (mM, measured by an enzymatic colorimetric assay) are summarized as median (inter-
quartile range) and differences compared with HC were assessed by MannWithney U test and
indicated as p<0.050, p<0.010, p<0.001.
(DOCX)
S2 Table. Individual and total NEFA serum levels in RA patients depending on their NEFA
profile. Serum levels of individual NEFA (μg/ml, measured by LC-MS/MS) and total NEFA
(mM, measured by an enzymatic colorimetric assay) are summarized as median (interquartile
range) and differences were assessed by MannWithney U test. Size effect was evaluated by
Hedges’g statistic.
(DOCX)
S3 Table. Individual and total NEFA serum levels in RA patients upon TNFα-blockade.
Serum levels of individual NEFA (μg/ml, measured by LC-MS/MS) and total NEFA (mM, mea-
sured by an enzymatic colorimetric assay) are summarized as median (interquartile range) and
differences were analyzed by paired T test.
(DOCX)
S4 Table. Individual and total NEFA serum levels in RA patients upon TNFα-blockade
stratified by their clinical response. Serum levels of individual NEFA (μg/ml, measured by
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LC-MS/MS) and total NEFA (mM, measured by an enzymatic colorimetric assay) are summa-
rized as median (interquartile range) and differences were analyzed by paired T test.
(DOCX)
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